News and Trends 29 Nov 2016 New British Partnership set to Cure Rare Diseases with Gene Therapy …also a big challenge. Oxford BioMedica seems like the perfect partner to ensure success: its versatile LentiVector platform is being used in clinical trials for Parkinson’s, several ocular diseases and… November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Pancreatic cancer microbiome discovery holds treatment hope …neurological diseases such as Alzheimer’s disease and Parkinson’s disease. “Our bacteriophage-based new drug is undoubtedly a ‘first-in-concept’ drug that can effectively control various immune-related diseases. Therefore, we will continue to… May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jun 2025 Pushing biotech forward in France: 18 companies to know about …neurodegenerative disorders like Alzheimer’s and Parkinson’s diseases. Cilcare is also conducting the SAPHIR observational study to explore the link between hearing impairments and neurodegenerative diseases. The study aims to develop… June 10, 2025 - 16 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 10 Dec 2024 Biotech in 2024: A retrospective …adults with advanced Parkinson’s disease, providing a new approach to managing this neurodegenerative disorder. Hympavzi – Pfizer: In October 2024, the FDA approved Hympavzi for treating adults and adolescents with… December 10, 2024 - 14 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2017 Meet these 5 Awesome Biotechs from Barcelona at BIO Europe Spring 2017 …is being tested in 3 Phase I trials to treat dementia (including Alzheimer’s and Parkinson’s), multiple sclerosis and Huntington’s. Minoryx Therapeutics is committed to finding innovative treatments for life-threatening… February 22, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 9 Sep 2019 4BIO Capital Raises €45M Fund to Invest in Advanced Therapies …accelerate the development of gene therapies for more common diseases, such as Parkinson’s disease. “We have a great opportunity to buck the trend,” Kuzmin said to me. “For the past… September 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2019 Update: The FDA Green-lights Clinical Trials for Huntington’s Disease Gene Therapy …like Parkinson’s, so perhaps their technology could be transferred across. The use of gene therapy to correct a gene mutation that can have such devastating effects will be an effective… January 23, 2019 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Weekly Roundup 15 Dec 2023 Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered …that treat a range of neurological conditions like schizophrenia, Parkinson’s disease, and mood disorders, hence widening AbbVie’s existing neuroscience portfolio. This means that AbbVie will own the rights to Cerevel’s… December 15, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jan 2017 The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge …after. Although its platform for inhibitors of the deubiquitinating enzyme (DUB) it still in preclinical stage, Mission Therapeutic’s already has two candidates, USP30 and USP7, lined up to target Parkinson’s… January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Nov 2024 Seven miRNA-focused companies pioneering new therapies in 2024 …program, reporting broad biodistribution across the brain and effective target engagement. These results support the progression of BMD-001 toward formal clinical studies for Alzheimer’s disease, ALS, and Parkinson’s disease. Cardior… November 26, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
2024 biotech deals tracker: the latest partnerships and M&A …November 2024: Vesalius, based in the United States, has partnered with GSK, based in the United Kingdom, to develop treatments for Parkinson’s disease. Vesalius is eligible to receive $80 million… March 7, 2024 - 1 minutemin - By Aurore Michelin Share WhatsApp Twitter Linkedin Email
Interview 10 Apr 2017 “Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec …planning to expand? Yes, but that requires money. We do have a very interesting candidate for Parkinson’s though, which outperforms LMTX to Alzheimer’s in an in vitro model. This is… April 10, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email